Neoantigen Targeted Therapies Market is estimated to be worth USD 3 Billion in 2030, predicts Roots Analysis
Advances in bioinformatics and genomic data analysis have enabled the identification of cancer antigens that are generally overlooked during immune surveillance; these neoantigens have been shown to possess substantial therapeutic potential
For more information, please visit https://www.rootsanalysis.com/....reports/view_documen
HPAPI and cytotoxic drugs contract manufacturing market is projected to reach USD 25 billion by 2030
Read Detailed Analysis: https://www.rootsanalysis.com/....reports/view_documen
Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract manufacturing market is projected to reach USD 25 billion by 2030, claims Roots Analysis
Fragment-Based Drug Discovery Market is estimated to be worth around USD 1.6 billion by 2030, predicts Roots Analysis
Roots Analysis is pleased to announce the publication of its recent study, titled, “Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030.”
Get Detailed Analysis: https://www.rootsanalysis.com/....reports/view_documen
Roots Analysis has done a detailed study on Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Get Detailed Analysis: https://www.rootsanalysis.com/....reports/view_documen
Oligonucleotide Synthesis, Modification and Purification Services Market is estimated to be worth USD 5.8 billion in 2030, predicts Roots Analysis
Read More: https://www.rootsanalysis.com/....reports/view_documen
The applications of oligonucleotides are vast, even beyond the life science / pharma sector; however, owing to complexities associated with the synthesis and processing of these molecules, such operations are usually outsourced to capable CMOs
